Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Yang, Longjiang ^a   Du, Juan ^a   Hou, Jian ^a   Jiang, Hua ^a   Zou, Jianfeng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PEPTIDE; PEPTIDE P [17-70]; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; VASCULOTROPIN; IMMUNOGLOBULIN LIGHT CHAIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIAL PROGENITOR CELL; GENE SEQUENCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE PF4; OVERALL SURVIVAL; TUMOR VOLUME; ANIMAL; CELL MOTION; CELL STRAIN HEK293; DISEASE MODEL; DRUG SCREENING; ENDOTHELIUM CELL; GENETICS; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; RABBIT; SURVIVAL; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MICE; MICE, NUDE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PLATELET FACTOR 4; RABBITS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959223711     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-261     Document Type: Article

References (31)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008, 111:2962-2972. 10.1182/blood-2007-10-078022, 2265446, 18332230.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
3. Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San MJ, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist 2010, 15:6-25. 10.1634/theoncologist.2009-0203, 20086168.
4. Kumar S, Rajkumar SV. Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Rev Anticancer Ther 2005, 5:759-766. 10.1586/14737140.5.5.759, 16221046.
5. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Reme T, De Vos J, Hundemer M, Condomines M, Bertsch U, Rossi JF, Jauch A, Klein B, Mohler T. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009, 114:128-143. 10.1182/blood-2008-10-184226, 19299335.
6. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201. 10.1038/nm1101-1194, 11689883.
7. Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E, Zhang Y, Liu Y, Li QQ. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 2003, 23:2481-2487.
8. Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 2005, 106:125-134. 10.1182/blood-2004-09-3679, 15741222.
9. Deuel TF, Keim PS, Farmer M, Heinrikson RL. Amino acid sequence of human platelet factor 4. Proc Natl Acad Sci USA 1977, 74:2256-2258. 10.1073/pnas.74.6.2256, 432148, 267922.
10. Hermodson M, Schmer G, Kurachi K. Isolation, crystallization, and primary amino acid sequence of human platelet factor 4. J Biol Chem 1977, 252:6276-6279.
11. Lasagni L, Grepin R, Mazzinghi B, Lazzeri E, Meini C, Sagrinati C, Liotta F, Frosali F, Ronconi E, Alain-Courtois N, Ballerini L, Netti GS, Maggi E, Annunziato F, Serio M, Romagnani S, Bikfalvi A, Romagnani P. PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood 2007, 109:4127-4134. 10.1182/blood-2006-10-052035, 17218382.
12. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990, 247:77-79. 10.1126/science.1688470, 1688470.
13. Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo. Mol Cancer Res 2010, 8:322-334. 10.1158/1541-7786.MCR-09-0176, 20215425.
14. Hagedorn M, Zilberberg L, Wilting J, Canron X, Carrabba G, Giussani C, Pluderi M, Bello L, Bikfalvi A. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res 2002, 62:6884-6890.
15. Perollet C, Han ZC, Savona C, Caen JP, Bikfalvi A. Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood 1998, 91:3289-3299.
16. Sato Y, Abe M, Takaki R. Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 1990, 172:595-600. 10.1016/0006-291X(90)90715-Y, 2173572.
17. Sulpice E, Bryckaert M, Lacour J, Contreres JO, Tobelem G. Platelet factor 4 inhibits FGF2-induced endothelial cell proliferation via the extracellular signal-regulated kinase pathway but not by the phosphatidylinositol 3-kinase pathway. Blood 2002, 100:3087-3094. 10.1182/blood.V100.9.3087, 12384403.
18. Jouan V, Canron X, Alemany M, Caen JP, Quentin G, Plouet J, Bikfalvi A. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 1999, 94:984-993.
19. Sulpice E, Contreres JO, Lacour J, Bryckaert M, Tobelem G. Platelet factor 4 disrupts the intracellular signalling cascade induced by vascular endothelial growth factor by both KDR dependent and independent mechanisms. Eur J Biochem 2004, 271:3310-3318. 10.1111/j.1432-1033.2004.04263.x, 15291808.
20. Cheng SH, Ng MH, Lau KM, Liu HS, Chan JC, Hui AB, Lo KW, Jiang H, Hou J, Chu RW, Wong WS, Chan NP, Ng HK. 4q loss is potentially an important genetic event in MM tumorigenesis: identification of a tumor suppressor gene regulated by promoter methylation at 4q13.3, platelet factor 4. Blood 2007, 109:2089-2099. 10.1182/blood-2006-04-018770, 17077331.
21. Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, Tan H, Pan X, Wu Z. Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009, 104:42-49. 10.1007/s00395-008-0738-8, 18622638.
22. Condon RG, Schaefer EJ, Santoro M, Longley R, Tsao YS, Zurawski SM, Liu Z. Development of a Chinese hamster ovary cell line for recombinant adenovirus-mediated gene expression. Biotechnol Prog 2003, 19:137-143. 10.1021/bp0200696, 12573016.
23. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 2004, 23:1547-1556. 10.1038/sj.emboj.7600145, 391059, 15029243.
24. Cui B, Johnson SP, Bullock N, Ali-Osman F, Bigner DD, Friedman HS. Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. Mol Pharmacol 2009, 75:1356-1363. 10.1124/mol.108.053124, 2684885, 19261750.
25. Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U, Norin AJ, Akman HO, Ozcelik T, Batuman OA. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005, 105:3286-3294. 10.1182/blood-2004-06-2101, 15618473.
26. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van RF, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002, 99:1745-1757. 10.1182/blood.V99.5.1745, 11861292.
27. Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 2004, 18:1891-1897. 10.1038/sj.leu.2403513, 15385929.
28. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006, 20:193-199. 10.1038/sj.leu.2404067, 16357836.
29. Tanaka T, Manome Y, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med 1997, 3:437-442. 10.1038/nm0497-437, 9095178.
30. Yamaguchi K, Ogawa K, Katsube T, Shimao K, Konno S, Shimakawa T, Yoshimatsu K, Naritaka Y, Yagawa H, Hirose K. Platelet factor 4 gene transfection into tumor cells inhibits angiogenesis, tumor growth and metastasis. Anticancer Res 2005, 25:847-851.
31. Benny O, Kim SK, Gvili K, Radzishevsky IS, Mor A, Verduzco L, Menon LG, Black PM, Machluf M, Carroll RS. In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model. FASEB J 2008, 22:488-499.